Bilirubin Market Size, Share Global Analysis Report, 2026-2034

Industry Insights

[238+ Pages Report] According to Facts & Factors, the global Bilirubin market size was estimated at USD 1.42 billion in 2025 and is expected to reach USD 2.68 billion by the end of 2034. The Bilirubin industry is anticipated to grow by a CAGR of 7.3% between 2026 and 2034. The Bilirubin Market is driven by increasing global focus on universal newborn screening and the growing burden of liver diseases requiring routine bilirubin monitoring.

Market Overview

The Bilirubin market comprises a wide array of diagnostic instruments, consumables, reagents, and software solutions designed to accurately quantify bilirubin concentration in blood, serum, plasma, or non-invasively through the skin. These technologies serve critical roles in early detection and ongoing management of hyperbilirubinemia in neonates to prevent kernicterus, as well as in diagnosing and monitoring various liver disorders, hemolytic conditions, and post-treatment recovery in adults and children. The market includes handheld transcutaneous devices for rapid bedside screening, automated high-throughput laboratory analyzers for precise fractionated bilirubin measurement, point-of-care cassettes for decentralized testing, and emerging connected platforms that integrate with electronic health records, all developed to meet stringent clinical accuracy, regulatory, and usability requirements across diverse healthcare environments.

Key Insights

• As per the analysis shared by our research analyst, the Bilirubin market is estimated to grow annually at a CAGR of around 7.3% over the forecast period (2026-2034).
• In terms of revenue, the Bilirubin market size was valued at around USD 1.42 billion in 2025 and is projected to reach USD 2.68 billion by 2034.
• The Bilirubin Market is driven by mandatory newborn jaundice screening programs and rising chronic liver disease prevalence.
• Based on the Type, the Transcutaneous Bilirubin Meters segment dominated the market in 2025 with a share of 56% due to non-invasive convenience, speed, and high adoption in neonatal care units worldwide.
• Based on the Application, the Neonatal Jaundice Screening segment dominated the market in 2025 with a share of 64%, owing to universal screening mandates and the critical need to prevent bilirubin encephalopathy in newborns.
• Based on the End-User, the Hospitals & Maternity Wards segment dominated the market in 2025 with a share of 52% because of high birth volumes, integrated newborn care protocols, and availability of multidisciplinary teams for immediate intervention.
• North America dominated the global Bilirubin market in 2025 with a share of 37% attributed to stringent newborn screening guidelines, advanced reimbursement frameworks, and early adoption of innovative non-invasive technologies.

Growth Drivers

• Universal Newborn Screening Expansion

Global health organizations and national policies increasingly mandate bilirubin screening for all newborns within the first few days of life, significantly boosting demand for both transcutaneous meters in delivery rooms and confirmatory laboratory analyzers.

Technological improvements in optical sensors and algorithms have enhanced transcutaneous accuracy across varying skin tones, building greater clinician trust and accelerating replacement cycles of older devices in maternity and pediatric departments.

Restraints

• Cost Barriers in Low- and Middle-Income Countries

Advanced transcutaneous bilirubinometers and automated analyzers require substantial capital investment and ongoing calibration, restricting their penetration in resource-constrained public health systems that rely on cheaper, less accurate visual or manual methods.

Limited trained personnel and inconsistent electricity supply in rural areas further complicate the deployment and maintenance of sophisticated bilirubin diagnostic equipment.

Opportunities

• Point-of-Care and Connected Device Growth

Development of compact, battery-operated, smartphone-connected bilirubin analyzers enables decentralized testing in community clinics and home settings, particularly valuable in geographies with limited laboratory access.

Integration of bilirubin data into digital health platforms and AI-based risk prediction tools creates opportunities for value-added services, remote monitoring subscriptions, and improved linkage to phototherapy or referral pathways.

Challenges

• Device Performance Variability and Standardization

Transcutaneous readings can vary due to factors such as skin thickness, melanin content, and ambient lighting, necessitating frequent confirmatory serum tests that reduce perceived efficiency and increase overall diagnostic costs.

Differing international regulatory standards, validation requirements across ethnic populations, and ongoing quality control demands create complexity for global manufacturers aiming for broad market access.

Report Scope

Report Attribute	Details
Market Size 2025	USD 1.42 Billion
Projected Market Size in 2034	USD 2.68 Billion
CAGR Growth Rate	7.3% CAGR
Base Year	2025
Forecast Years	2026-2034
Key Market Players	Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Drägerwerk AG & Co. KGaA, Natus Medical Incorporated, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Advanced Instruments, LLC, AVI Healthcare Pvt. Ltd., Beckman Coulter, Inc., Das S.r.l., and Others.
Key Segment	By Type, By Application, By End-User, and By Region
Major Regions Covered	North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
Purchase Options	Request customized purchase options to meet your research needs. Explore purchase options

Market Segmentation

The Bilirubin market is segmented by type, application, end-user, and region.

Based on Type Segment, the Bilirubin market is divided into transcutaneous bilirubin meters, serum/plasma bilirubin analyzers, benchtop biochemical analyzers, point-of-care bilirubin devices, and others. The most dominant segment is Transcutaneous Bilirubin Meters, followed by Serum/Plasma Bilirubin Analyzers. Transcutaneous Bilirubin Meters dominate because they offer immediate, painless, blood-free screening that aligns perfectly with busy maternity wards and outpatient pediatric clinics, significantly reducing the need for invasive tests in low-risk cases, improving workflow efficiency, lowering infection risks, and driving widespread adoption through cost savings and better parental acceptance, thereby fueling overall market volume and innovation.

Based on Application Segment, the Bilirubin market is divided into neonatal jaundice screening, liver function testing, hemolytic disease monitoring, post-surgical monitoring, and others. The most dominant segment is Neonatal Jaundice Screening, followed by Liver Function Testing. Neonatal Jaundice Screening leads the segment due to extremely high incidence rates in the first week of life, global clinical guidelines recommending universal screening, and the severe preventable consequence of untreated high bilirubin (kernicterus), which creates non-discretionary demand for frequent, reliable testing devices and sustains high consumption of both screening meters and confirmatory reagents across healthcare systems worldwide.

Based on End-User Segment, the Bilirubin market is divided into hospitals & maternity wards, diagnostic laboratories, specialty clinics, home care & community health, and others. The most dominant segment is Hospitals & Maternity Wards, followed by Diagnostic Laboratories. Hospitals & Maternity Wards dominate because they serve as the primary location for deliveries and immediate postnatal care, where bilirubin screening is performed routinely on nearly every newborn, enabling centralized procurement of large device fleets, integration with electronic medical records, and rapid clinical decision-making for phototherapy initiation, which together drive consistent high-volume utilization and stimulate continuous upgrades to the latest non-invasive and automated technologies.

Recent Developments

• In January 2026, Philips expanded its BilEclipse transcutaneous bilirubinometer line with a new model featuring multi-wavelength optics for improved performance across all skin tones and Bluetooth connectivity for hospital EMR integration.
• In November 2025, Roche Diagnostics launched an enhanced bilirubin module for its cobas® pro integrated solutions analyzer, delivering faster fractionated bilirubin results with reduced interference in high-throughput clinical laboratories.
• In August 2025, Natus Medical received CE marking and launched its next-generation NeoBLUE transcutaneous bilirubin device optimized for preterm and low-birth-weight infants in European and Asian markets.
• In April 2026, Mindray introduced a compact point-of-care bilirubin analyzer with built-in quality control and LIS connectivity targeted at mid-sized hospitals and community health centers in emerging markets.
• In March 2026, Advanced Instruments partnered with regional distributors to roll out cost-optimized benchtop bilirubin analyzers specifically designed for public-sector neonatal screening programs in Southeast Asia and Africa.

Regional Analysis

• North America to dominate the global market

North America maintains leadership in the Bilirubin market through rigorous implementation of universal newborn screening protocols endorsed by major pediatric societies, widespread insurance coverage for both screening and confirmatory testing, and high clinician preference for non-invasive technologies that reduce unnecessary blood draws. Advanced hospital infrastructure, strong focus on patient safety, and substantial R&D investment by domestic manufacturers further accelerate innovation and early adoption. The United States dominates within North America owing to its large annual birth cohort, extensive network of level-III NICUs, proactive American Academy of Pediatrics guidelines mandating bilirubin risk assessment, and a robust reimbursement environment that supports procurement of premium transcutaneous meters and automated analyzers across public and private healthcare facilities.

Europe exhibits strong and stable growth in the Bilirubin market, supported by harmonized medical device regulations, comprehensive public health insurance covering neonatal screening, and emphasis on evidence-based preventive care in maternity services. Collaborative research networks and centralized procurement systems facilitate standardized adoption across countries. Germany dominates within Europe through its leadership in precision medical devices, strict quality certification processes that build global trust, and significant public investment in maternal and child health programs that prioritize early jaundice detection and treatment.

Asia Pacific is the fastest-growing region in the Bilirubin market, driven by massive birth volumes, increasing urbanization and hospital deliveries, government-led newborn health initiatives, and rising awareness of jaundice-related risks among parents and providers. Domestic manufacturing capabilities are improving affordability and availability. China dominates within Asia Pacific with its enormous population, rapid expansion of urban maternity hospitals, national policies promoting standardized neonatal screening, and growing domestic production of cost-effective transcutaneous devices that serve both internal demand and export markets across the region.

Latin America shows accelerating progress in the Bilirubin market, fueled by improving neonatal care standards, expansion of public health insurance coverage, and international support for maternal-child health programs. Increasing private-sector participation introduces advanced technologies in urban centers. Brazil dominates the region with its large population, strengthening organized healthcare networks, and active integration of bilirubin screening into routine postnatal protocols in both public maternity hospitals and private clinics.

The Middle East & Africa region demonstrates emerging momentum in the Bilirubin market, supported by rising healthcare expenditure, focus on reducing infant mortality, and strategic partnerships introducing modern diagnostic tools. Urban tertiary hospitals are adopting non-invasive screening while rural programs expand gradually. The United Arab Emirates leads within the region through its world-class healthcare facilities, emphasis on advanced pediatric services, and government vision to establish comprehensive newborn screening frameworks incorporating the latest bilirubin monitoring technologies.

Competitive Analysis

The global Bilirubin market is dominated by players:

• Koninklijke Philips N.V.
• F. Hoffmann-La Roche Ltd.
• Drägerwerk AG & Co. KGaA
• Natus Medical Incorporated
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Siemens Healthineers AG
• Advanced Instruments, LLC
• AVI Healthcare Pvt. Ltd.
• Beckman Coulter, Inc.
• Das S.r.l.

The global Bilirubin market is segmented as follows:

By Type

• Transcutaneous Bilirubin Meters
• Serum/Plasma Bilirubin Analyzers
• Benchtop Biochemical Analyzers
• Point-of-Care Bilirubin Devices
• Others

By Application

• Neonatal Jaundice Screening
• Liver Function Testing
• Hemolytic Disease Monitoring
• Post-Surgical Monitoring
• Others

By End-User

• Hospitals & Maternity Wards
• Diagnostic Laboratories
• Specialty Clinics
• Home Care & Community Health
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America